Vitamin K

• 

  Subject Areas on Research

  • A model for the tissue factor pathway to thrombin. I. An empirical study. 
  • Addressing barriers to optimal oral anticoagulation use and persistence among patients with atrial fibrillation: Proceedings, Washington, DC, December 3-4, 2012. 
  • All-Cause Mortality and Cardiovascular Outcomes With Non-Vitamin K Oral Anticoagulants Versus Warfarin in Patients With Heart Failure in the Food and Drug Administration Adverse Event Reporting System. 
  • An updated meta-analysis of novel oral anticoagulants versus vitamin K antagonists for uninterrupted anticoagulation in atrial fibrillation catheter ablation. 
  • Antithrombotic Therapy after Acute Coronary Syndrome or PCI in Atrial Fibrillation. 
  • Antithrombotic Therapy in Patients With Atrial Fibrillation and Acute Coronary Syndrome Treated Medically or With Percutaneous Coronary Intervention or Undergoing Elective Percutaneous Coronary Intervention: Insights From the AUGUSTUS Trial. 
  • Antithrombotic therapies in patients with prosthetic heart valves: guidelines translated for the clinician. 
  • Antithrombotic treatment gap among patients with atrial fibrillation and type 2 diabetes. 
  • Antithrombotic treatment strategies after PCI. 
  • Apixaban in patients at risk of stroke undergoing atrial fibrillation ablation. 
  • Association of Intracerebral Hemorrhage Among Patients Taking Non-Vitamin K Antagonist vs Vitamin K Antagonist Oral Anticoagulants With In-Hospital Mortality. 
  • Atrial fibrillation and stroke severity: expanding the mechanistic exemplar, clinical phenotype, and goals of anticoagulant pharmacotherapy. 
  • Balancing Bleeding and Clotting: The Known Unknowns of Mechanically Assisted Circulation. 
  • Bleeding risk in warfarinized patients with a therapeutic international normalized ratio: the effect of low factor IX levels. 
  • Chronic vitamin K antagonist therapy and bleeding risk in ST elevation myocardial infarction patients. 
  • Clinical events after transitioning from apixaban versus warfarin to warfarin at the end of the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial. 
  • Clinical outcomes with rivaroxaban in patients transitioned from vitamin K antagonist therapy: a subgroup analysis of a randomized trial. 
  • Cloning and characterization of the 5' end (exon 1) of the gene encoding human factor X. 
  • Clopidogrel plus aspirin in atrial fibrillation. 
  • Comment: Decreased warfarin effect after initiation of high-protein, low-carbohydrate diets. 
  • Comparison of international normalized ratio audit parameters in patients enrolled in GARFIELD-AF and treated with vitamin K antagonists. 
  • Continuous anticoagulation with catheter ablation: answers and questions. 
  • D-dimer and risk of thromboembolic and bleeding events in patients with atrial fibrillation--observations from the ARISTOTLE trial. 
  • DT diaphorase [NAD(P)H: (quinone acceptor) oxidoreductase] facilitates redox cycling of menadione in channel catfish (Ictalurus punctatus) cytosol. 
  • Digoxin use in patients with atrial fibrillation and adverse cardiovascular outcomes: a retrospective analysis of the Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF). 
  • Direct oral anticoagulant- versus vitamin K antagonist-related gastrointestinal bleeding: Insights from a nationwide cohort. 
  • Dronedarone and vitamin K antagonists: a review of drug-drug interactions. 
  • Effects of prothrombin complex concentrate and recombinant activated factor VII on vitamin K antagonist induced anticoagulation. 
  • Efficacy and safety of rivaroxaban compared with warfarin among elderly patients with nonvalvular atrial fibrillation in the Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF). 
  • Efficacy and safety of rivaroxaban in patients with diabetes and nonvalvular atrial fibrillation: the Rivaroxaban Once-daily, Oral, Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF Trial). 
  • End of study transition from study drug to open-label vitamin K antagonist therapy: the ROCKET AF experience. 
  • Factors associated with major bleeding events: insights from the ROCKET AF trial (rivaroxaban once-daily oral direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation). 
  • Factors associated with non-vitamin K antagonist oral anticoagulants for stroke prevention in patients with new-onset atrial fibrillation: Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II (ORBIT-AF II). 
  • Glutathione-dependent defense in channel catfish (Ictalurus punctatus) and brown bullhead (Ameriurus nebulosus). 
  • Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes. 
  • HEPATIC ALDEHYDE OXIDASE. II. DIFFERENTIAL INHIBITION OF ELECTRON TRANSFER TO VARIOUS ELECTRON ACCEPTORS. 
  • Heparin-induced thrombocytopenia: when a low platelet count is a mandate for anticoagulation. 
  • Higher risk of death and stroke in patients with persistent vs. paroxysmal atrial fibrillation: results from the ROCKET-AF Trial. 
  • Hospitalization Among Patients With Atrial Fibrillation and a Recent Acute Coronary Syndrome or Percutaneous Coronary Intervention Treated With Apixaban or Aspirin: Insights From the AUGUSTUS Trial. 
  • Idarucizumab for Dabigatran Reversal in the Management of Patients With Gastrointestinal Bleeding. 
  • Intracranial hemorrhage among patients with atrial fibrillation anticoagulated with warfarin or rivaroxaban: the rivaroxaban once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation. 
  • Management of Major Bleeding in Patients With Atrial Fibrillation Treated With Non-Vitamin K Antagonist Oral Anticoagulants Compared With Warfarin in Clinical Practice (from Phase II of the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation [ORBIT-AF II]). 
  • Management of major bleeding events in patients treated with rivaroxaban vs. warfarin: results from the ROCKET AF trial. 
  • Noncentral Nervous System Systemic Embolism in Patients With Atrial Fibrillation: Results From ROCKET AF (Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation). 
  • Off-Label Dosing of Non-Vitamin K Antagonist Oral Anticoagulants and Adverse Outcomes: The ORBIT-AF II Registry. 
  • Outcome of Patients Receiving Thrombolytic Therapy While on Rivaroxaban for Nonvalvular Atrial Fibrillation (from Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation). 
  • Outcomes of temporary interruption of rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation: results from the rivaroxaban once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation (ROCKET AF). 
  • Overlapping specificities of base excision repair, nucleotide excision repair, recombination, and translesion synthesis pathways for DNA base damage in Saccharomyces cerevisiae. 
  • Percutaneous coronary interventions in patients with heparin-induced thrombocytopenia. 
  • Perioperative hemostatic management of patients treated with vitamin K antagonists. 
  • Perioperative management of anticoagulation: guidelines translated for the clinician. 
  • Perioperative management of patients on chronic antithrombotic therapy. 
  • Periprocedural management of patients receiving a vitamin K antagonist or a direct oral anticoagulant requiring an elective procedure or surgery. 
  • Potassium Measures and Their Associations with Glucose and Diabetes Risk: The Multi-Ethnic Study of Atherosclerosis (MESA). 
  • Prothrombin Complex Concentrates for Perioperative Vitamin K Antagonist and Non-vitamin K Anticoagulant Reversal. 
  • Quality of clinical documentation and anticoagulation control in patients with chronic nonvalvular atrial fibrillation in routine medical care. 
  • Rationale and design of AXAFA-AFNET 5: an investigator-initiated, randomized, open, blinded outcome assessment, multi-centre trial to comparing continuous apixaban to vitamin K antagonists in patients undergoing atrial fibrillation catheter ablation. 
  • Reasons for Refusal of Newborn Vitamin K Prophylaxis: Implications for Management and Education. 
  • Recurrent venous thromboembolism in anticoagulated patients with cancer: management and short-term prognosis. 
  • Relation of Risk of Stroke in Patients With Atrial Fibrillation to Body Mass Index (from Patients Treated With Rivaroxaban and Warfarin in the Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation Trial). 
  • Renal dysfunction as a predictor of stroke and systemic embolism in patients with nonvalvular atrial fibrillation: validation of the R(2)CHADS(2) index in the ROCKET AF (Rivaroxaban Once-daily, oral, direct factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation) and ATRIA (AnTicoagulation and Risk factors In Atrial fibrillation) study cohorts. 
  • Response to letter regarding article, "renal dysfunction as a predictor of stroke and systemic embolism in patients with nonvalvular atrial fibrillation: validation of the R2CHADS2 index in the ROCKET AF (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation) and ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) study cohorts". 
  • Rhythm control in atrial fibrillation. 
  • Rivaroxaban for stroke prevention in East Asian patients from the ROCKET AF trial. 
  • Rivaroxaban-once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation: rationale and design of the ROCKET AF study. 
  • Self-monitoring of oral anticoagulation: systematic review and meta-analysis of individual patient data. 
  • Stent Thrombosis in Patients With Atrial Fibrillation Undergoing Coronary Stenting in the AUGUSTUS Trial. 
  • Surface-dependent hemostasis. 
  • The perioperative management of antithrombotic therapy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). 
  • The pharmacology of novel oral anticoagulants. 
  • The role of the membrane in the expression of the vitamin K-dependent enzymes. 
  • Treatment Consistency Across Levels of Baseline Renal Function With Rivaroxaban or Warfarin: A ROCKET AF (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation) Analysis. 
  • Update of the guidelines for lupus anticoagulant detection. Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis. 
  • Updates in the perioperative and emergency management of non-vitamin K antagonist oral anticoagulants. 
  • Use of Direct Oral Anticoagulants in Special Populations. 
  • Use of Dual Antiplatelet Therapy and Patient Outcomes in Those Undergoing Percutaneous Coronary Intervention: The ROCKET AF Trial. 
  • Vitamins E and K induce aryl hydrocarbon hydroxylase activity in human cell cultures. 
  • Warfarin and acetaminophen interaction: a summary of the evidence and biologic plausibility. 
  • Why develop antidotes and reversal agents for non-vitamin K oral anticoagulants? 
  • [Antiplatelet and anticoagulant therapy for stroke prevention in patients with non-valvular atrial fibrillation: evidence based strategies and new developments]. 
  • n-3 Canola oil effectively replaces fish oil as a new safe dietary source of DHA in feed for juvenile Atlantic salmon. 
• 

  Keywords of People

  • Granger, Christopher Bull, Professor of Medicine, School of Nursing